Marcos A Espinal

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. ncbi request reprint Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance
    M A Espinal
    Communicable Diseases Cluster, World Health Organization, Geneva, Switzerland
    N Engl J Med 344:1294-303. 2001
  2. ncbi request reprint Can DOTS control multidrug-resistant tuberculosis?
    Marcos A Espinal
    Stop TB Partnership, World Health Organization, CH 1211 Geneva, Switzerland
    Lancet 365:1206-9. 2005
  3. ncbi request reprint The global situation of MDR-TB
    Marcos A Espinal
    Tuberculosis Strategy and Operations, Stop TB Department, World Health Organization, Ave Appia 22, Geneva 1211, Switzerland
    Tuberculosis (Edinb) 83:44-51. 2003
  4. pmc Multidrug-resistant tuberculosis management in resource-limited settings
    Eva Nathanson
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Emerg Infect Dis 12:1389-97. 2006
  5. ncbi request reprint Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis
    Christopher Dye
    Communicable Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    Science 295:2042-6. 2002
  6. ncbi request reprint Increasing transparency in partnerships for health--introducing the Green Light Committee
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Trop Med Int Health 7:970-6. 2002
  7. ncbi request reprint Rebuttal: Evidence and uncertainties
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 6:651-3. 2002
  8. ncbi request reprint Worldwide incidence of multidrug-resistant tuberculosis
    Christopher Dye
    Communicable Diseases, World Health Organization, 1211 Geneva 27, Switzerland
    J Infect Dis 185:1197-202. 2002
  9. ncbi request reprint Tuberculosis as a major global health problem in the 21st century: a WHO perspective
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Semin Respir Crit Care Med 25:245-53. 2004
  10. ncbi request reprint Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
    Pedro G Suarez
    National Tuberculosis Control Programme, Ministry of Health, Lima, Peru
    Lancet 359:1980-9. 2002

Detail Information

Publications13

  1. ncbi request reprint Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance
    M A Espinal
    Communicable Diseases Cluster, World Health Organization, Geneva, Switzerland
    N Engl J Med 344:1294-303. 2001
    ..Data on global trends in resistance to antituberculosis drugs are lacking...
  2. ncbi request reprint Can DOTS control multidrug-resistant tuberculosis?
    Marcos A Espinal
    Stop TB Partnership, World Health Organization, CH 1211 Geneva, Switzerland
    Lancet 365:1206-9. 2005
  3. ncbi request reprint The global situation of MDR-TB
    Marcos A Espinal
    Tuberculosis Strategy and Operations, Stop TB Department, World Health Organization, Ave Appia 22, Geneva 1211, Switzerland
    Tuberculosis (Edinb) 83:44-51. 2003
    ..Adoption of DOTS to prevent the generation of resistant strains and careful introduction of second-line drugs to treat patients with MDR are the top priorities for proper control/containment of MDR-TB...
  4. pmc Multidrug-resistant tuberculosis management in resource-limited settings
    Eva Nathanson
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Emerg Infect Dis 12:1389-97. 2006
    ..In resource-limited settings, treatment of MDRTB provided through, or in collaboration with, national TB programs can yield results similar to those from wealthier settings...
  5. ncbi request reprint Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis
    Christopher Dye
    Communicable Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    Science 295:2042-6. 2002
    ....
  6. ncbi request reprint Increasing transparency in partnerships for health--introducing the Green Light Committee
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Trop Med Int Health 7:970-6. 2002
    ..The GLC mechanism may be useful in the development of other partnerships needed in the rational allocation of resources and tools for combating additional infectious diseases...
  7. ncbi request reprint Rebuttal: Evidence and uncertainties
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 6:651-3. 2002
  8. ncbi request reprint Worldwide incidence of multidrug-resistant tuberculosis
    Christopher Dye
    Communicable Diseases, World Health Organization, 1211 Geneva 27, Switzerland
    J Infect Dis 185:1197-202. 2002
    ..2% of all new TB cases. The analysis provides the first comprehensive set of estimates of the MDR TB burden by country and globally...
  9. ncbi request reprint Tuberculosis as a major global health problem in the 21st century: a WHO perspective
    Rajesh Gupta
    World Health Organization, Geneva, Switzerland
    Semin Respir Crit Care Med 25:245-53. 2004
    ....
  10. ncbi request reprint Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
    Pedro G Suarez
    National Tuberculosis Control Programme, Ministry of Health, Lima, Peru
    Lancet 359:1980-9. 2002
    ....
  11. ncbi request reprint The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century
    J Peter Cegielski
    Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Infect Dis Clin North Am 16:1-58. 2002
    ..Still, recent developments in immunology, biochemistry, and molecular biology suggest that new knowledge and tools are just around the corner. These will enhance the ability to conquer this microbe by the end of the current century...
  12. ncbi request reprint Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment
    Marcos A Espinal
    Int J Tuberc Lung Dis 7:607-8. 2003
  13. ncbi request reprint Eliminating tuberculosis: the time has come for business 'unusual'
    Marcos A Espinal
    Int J Tuberc Lung Dis 8:275. 2004